Novo Nordisk offers Wegovy and Ozempic at $199/month for new self-pay patients, valid for the first two months until March 31 ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk announced that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy(R) and Ozempic(R) for only $199 each beginning November 17, 2025 -- Also effective November 17, ...

Novo Nordisk continued its startling campaign to snatch a promising obesity biotech from Pfizer on Tuesday, raising its offer to more than 30% above what Pfizer had initially agreed to pay, not ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

President Trump wants to cut the price of Ozempic to $150. While that could be an issue for Novo Nordisk, it should find a way to navigate ongoing price negotiations. 10 stocks we like better than ...

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In early June, a deal between ...

Novo Nordisk will soon present phase 3 clinical trial results for semaglutide for early Alzheimer's disease, but expectations for positive results are relatively low. Semaglutide may reduce the risk ...